

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



Naloxegol-d₅ (oxalate)

Item No. 29578

(4R,4aS,7S,7aR,12bS)-7-((2,5,8,11,14,17,20-Formal Name:

> heptaoxadocosan-22-yl)oxy)-3-(allyl-d5)-1,2,3,4,5,6,7,7a-octahydro-4aH-4,12methanobenzofuro[3,2-e]isoquinoline-4a,9-

diol, monoethanedioate

MF: $C_{34}H_{48}D_5NO_{11} \bullet C_2H_2O_4$

FW: 746.9


Chemical Purity: ≥98% (Naloxegol)

Deuterium

Incorporation: \geq 99% deuterated forms (d₁-d₅); \leq 1% d₀

Supplied as: A solid Storage: -20°C Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

Naloxegol-d₅ (oxalate) is intended for use as an internal standard for the quantification of naloxegol (Item No. 23731) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Naloxegol- d_{ς} (oxalate) is supplied as a solid. A stock solution may be made by dissolving the naloxegol- d_{ς} (oxalate) in the solvent of choice, which should be purged with an inert gas. Naloxegol- d_5 (oxalate) is soluble in the organic solvent DMSO.

Description

Naloxegol is a peripherally acting antagonist of the μ -opioid receptor (K_i = 7.42 nM; pA₂ = 7.95). It is selective for the μ -opioid receptor over the δ -opioid receptor ($K_i = 866$ nM). Naloxegol also acts as a partial agonist of κ -opioid receptors in vitro (EC₅₀ = 47 nM for [35 S]GTP γ S binding) but lacks activity ex vivo at concentrations up to 10 µM. In vivo, naloxegol reverses morphine-induced decreases in gastrointestinal motility and analgesia in a hot-plate assay in rats (ED_{50} s = 23.1 and 55.4 mg/kg, respectively), demonstrating a two-fold separation for peripheral versus CNS effects. Naloxegol also exhibits a brain uptake rate comparable to atenolol, a low-permeation standard with no brain uptake, in a rat brain perfusion model.

Reference

1. Floettmann, E., Bui, K., Sostek, M., et al. Pharmacologic profile of naloxegol, a peripherally acting μ-opioid receptor antagonist, for the treatment of opioid-induced constipation. J. Pharmacol. Exp. Ther. 361(2), 280-291 (2017).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 01/13/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM